Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
96-week open-label extension study of apricitabine in treatment-experienced HIV-1 infected patients
2008-001486-28Phase 3Terminated
- Sponsor
- Avexa Limited
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apricitabine in human immunodeficiency virus infection (HIV), sponsored by Avexa Limited. Primary endpoint: Primary safety endpoint. Started Apr 2008; status: terminated.
02
Drugs
apricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-001486-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001486-28.